Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Relypsa: Analyzing March Results of the Veltassa Launch (RLYP, Buy, $17.60)

Investment Perspective

Investors are closely watching the launch progress of Veltassa following its December 2015 introduction. Medicare and managed care have…
Read more…